Core Viewpoint - The company is taking steps to reduce drug prices in response to the upcoming deadline set by the Trump administration [1] Group 1 - The company is identified as a major player in the pharmaceutical industry [1] - The price-cutting initiative aligns with broader industry trends as other pharmaceutical giants are also making similar moves [1] - The actions are being taken ahead of a regulatory deadline, indicating a proactive approach to compliance [1]